Wonbiogen Co.,Ltd. Logo

Wonbiogen Co.,Ltd.

Develops and manufactures advanced wound care solutions and medical materials.

307280 | KO

Overview

Corporate Details

ISIN(s):
KR7307280008
LEI:
Country:
South Korea
Address:
경상북도 구미시 1공단로5길 56 ㈜원바이오젠, 구미시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Established in 2006, Wonbiogen Co., Ltd. is a bio-venture company specializing in the research, development, and manufacturing of advanced medical materials. The company's primary focus is on science-driven, advanced wound care solutions. Its product portfolio includes polyurethane foam dressings, hydrocolloid dressings, and soft silicone adhesive products under brands such as MEDISORB and RENODERM. These products are designed to treat a wide range of wounds, from cuts and burns to surgical sites and chronic ulcers. Wonbiogen leverages its expertise in developing highly biocompatible medical macromolecules to create innovative medical supplies and also offers OEM services.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-27 00:00
Share Issue/Capital Change
[기재정정]주식소각결정
Korean 13.0 KB
2025-08-26 00:00
Regulatory Filings
신규시설투자등(자율공시)
Korean 7.5 KB
2025-08-25 00:00
Legal Proceedings Report
불성실공시법인미지정 (지정유예)
Korean 5.5 KB
2025-08-19 00:00
Share Issue/Capital Change
주식소각결정
Korean 9.9 KB
2025-08-13 00:00
Interim / Quarterly Report
반기보고서 (2025.06)
Korean 1.3 MB
2025-08-01 00:00
Legal Proceedings Report
불성실공시법인지정예고 (공시불이행)
Korean 4.9 KB
2025-07-07 00:00
Legal Proceedings Report
소송등의제기ㆍ신청(일정금액이상의청구)
Korean 7.2 KB
2025-07-07 00:00
Legal Proceedings Report
소송등의판결ㆍ결정
Korean 5.3 KB
2025-05-23 00:00
Delisting Announcement
주권매매거래정지해제 (액면병합 주권 변경상장)
Korean 4.3 KB
2025-05-14 00:00
Quarterly Report
분기보고서 (2025.03)
Korean 1.2 MB
2025-04-29 00:00
Delisting Announcement
주권매매거래정지 (주식의 병합, 분할 등 전자등록 변경, 말소)
Korean 4.6 KB
2025-03-31 00:00
AGM Information
정기주주총회결과
Korean 21.2 KB
2025-03-20 00:00
Audit Report / Information
감사보고서제출
Korean 25.0 KB
2025-03-20 00:00
Audit Report / Information
사업보고서 (2024.12)
Korean 441.3 KB
2025-03-14 00:00
Pre-Annual General Meeting Information
주주총회소집결의
Korean 8.6 KB

Automate Your Workflow. Get a real-time feed of all Wonbiogen Co.,Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Wonbiogen Co.,Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Wonbiogen Co.,Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Advicenne Logo
Develops and commercializes therapies for rare renal diseases for patients of all ages.
France
ALDVI
AegirBio AB Logo
Develops user-friendly, saliva-based tests for health monitoring & therapeutic drug monitoring.
Sweden
AEGIR
Aelis Farma Logo
Developing novel CB1 receptor inhibitors for treating brain and CNS disorders.
France
AELIS
AEON Biopharma, Inc. Logo
Developing therapeutic neurotoxins for medical conditions like migraines and cervical dystonia.
United States of America
AEON
AFC-HD AMS Life Science Co.,Ltd. Logo
An OEM of health foods, supplements, and cosmetics, managing the full value chain from R&D to sales.
Japan
2927
AGENUS INC Logo
Develops antibodies, cell therapies & adjuvants to harness the immune system against cancer.
United States of America
AGEN
AGIOS PHARMACEUTICALS, INC. Logo
Pioneering cellular metabolism therapies for rare, genetically defined diseases like anemias.
United States of America
AGIO
Akari Therapeutics Plc Logo
A clinical-stage oncology company developing next-gen ADCs for targeted cancer therapy.
United States of America
AKTX
Akebia Therapeutics, Inc. Logo
Developing and commercializing novel, FDA-approved therapeutics for kidney disease.
United States of America
AKBA

Talk to a Data Expert

Have a question? We'll get back to you promptly.